MUTATED ANTI-TNFa ANTIBODIES AND METHODS OF THEIR USE
AssigneeAbbVie Inc.
InventorsChris M. Chumsae, Zehra Kaymakcalan
Life of this patent
Estimating the term…
Abstract
The present invention is directed to modified antibodies, including anti-TNFα antibodies, in which C-terminal amino acids of heavy chain sequences are modified from a native sequence of proline-glycine-lysine (“PGK”) to one that includes a proline positioned between the glycine and lysine, resulting in a C-terminal sequence of proline-glycine-proline-lycine (“PGPK”). The invention further provides methods of producing and using such antibodies.
Claims30
An antibody, or antigen-binding portion thereof, comprising a C-terminal heavy chain sequence of proline-glycine-proline-lysine (PGPK) (SEQ ID NO:9).
A composition comprising an antibody, or antigen-binding portion thereof, wherein the composition comprises less than about 50% lysine variant species that lack a C-terminal lysine (Lys 0).
A composition comprising an antibody, or antigen-binding portion thereof, wherein the composition comprises at least about 70% lysine variant species that have two C-terminal lysines (Lys 2).
Dependencies are inferred from the claim text.